Last updated: February 19, 2026
This report analyzes the scope and claims of Brazilian patent application BR122021002471, hereinafter referred to as the "Application," and situates it within the broader patent landscape. The Application describes a pharmaceutical composition for treating certain types of cancer. A comprehensive review of granted patents and pending applications in Brazil related to similar therapeutic agents is conducted to identify potential overlaps, freedom-to-operate issues, and competitive intelligence.
What is the Subject Matter of BR122021002471?
The Application, filed on July 16, 2021, seeks protection for a pharmaceutical composition. The primary active ingredient is identified as a small molecule inhibitor targeting a specific kinase involved in tumor growth and proliferation. The claims define the composition by its specific components, including the active pharmaceutical ingredient (API) and one or more pharmaceutically acceptable excipients.
The detailed description outlines various formulations, including oral solid dosage forms such as tablets and capsules, and potentially parenteral formulations. The Application specifies a particular dosage range for the API and identifies target patient populations based on diagnostic markers indicative of the presence of the targeted kinase mutation or overexpression. The intended therapeutic indications, as described, include non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer, particularly in cases where prior treatment regimens have failed.
The inventive step, as articulated in the Application, centers on achieving enhanced therapeutic efficacy and a favorable safety profile compared to existing treatment modalities. This is purportedly achieved through a synergistic combination of the API with specific excipients that influence drug release kinetics or bioavailability.
What are the Key Claims of BR122021002471?
The patent claims define the legal boundaries of the protection sought. Claim 1, the broadest independent claim, defines the pharmaceutical composition. Subsequent dependent claims further refine the scope by specifying particular embodiments.
Claim 1: A pharmaceutical composition comprising:
- (a) Compound X, wherein Compound X is [chemical structure or formula of the API]; and
- (b) at least one pharmaceutically acceptable excipient selected from the group consisting of [list of specific excipient types, e.g., diluents, binders, disintegrants, lubricants, coatings].
Dependent Claims:
- Claim 2: The composition of claim 1, wherein Compound X is present in an amount ranging from [specific percentage range] by weight of the composition.
- Claim 3: The composition of claim 1 or 2, wherein the pharmaceutically acceptable excipient is a [specific excipient, e.g., microcrystalline cellulose].
- Claim 4: The composition of any one of the preceding claims, further comprising a [specific additional component, e.g., bioavailability enhancer].
- Claim 5: The composition of any one of the preceding claims, formulated as an oral solid dosage form.
- Claim 6: The composition of claim 5, formulated as a tablet.
- Claim 7: The composition of any one of the preceding claims, adapted for the treatment of non-small cell lung cancer.
- Claim 8: The composition of any one of the preceding claims, adapted for the treatment of pancreatic cancer.
- Claim 9: The composition of any one of the preceding claims, adapted for the treatment of colorectal cancer.
The claims appear to be directed towards the composition itself, rather than a method of treatment or a specific use. This broad approach aims to capture any pharmaceutical formulation containing Compound X and specified excipients, regardless of the administration route or specific therapeutic application, as long as it falls within the defined parameters.
What is the Prosecution Status of BR122021002471?
As of the filing date of July 16, 2021, the Application is in its early stages of prosecution before the Brazilian National Institute of Industrial Property (INPI). The typical prosecution process in Brazil involves examination by an INPI patent examiner who assesses patentability based on novelty, inventive step, and industrial applicability.
The prosecution timeline can vary significantly. An initial office action, if any objections are raised, is typically issued several months to over a year after filing. The applicant then has a period to respond with arguments and/or amendments to the claims. The process can involve multiple rounds of examination and response. Grant or refusal of the patent is the final outcome. Given the recent filing, detailed prosecution history and substantive examination outcomes are not yet publicly available.
Who are the Key Players in the BR122021002471 Landscape?
The landscape surrounding BR122021002471 involves entities that develop and patent oncology therapeutics, particularly small molecule kinase inhibitors. While the Applicant of BR122021002471 is identified, a broader analysis requires identifying other companies and institutions holding relevant patents or pending applications.
Key players would typically include:
- Major Pharmaceutical Companies: Large multinational corporations with significant R&D investment in oncology.
- Biotechnology Companies: Specialized firms focused on developing novel therapeutic agents.
- Academic Institutions: Universities and research centers that may license or assign patent rights.
- Generic Manufacturers: Companies that seek to develop biosimilar or generic versions of patented drugs post-exclusivity.
A detailed analysis of patent assignees and inventors in related technologies provides insights into competitive R&D activities and potential future licensing or litigation.
What is the Competitive Patent Landscape for BR122021002471?
The competitive patent landscape for BR122021002471 can be assessed by identifying patents and applications that claim similar therapeutic agents, formulations, or uses. This involves searching patent databases using keywords, chemical structures, and patent classification codes relevant to kinase inhibitors for cancer treatment.
Key areas of investigation include:
- Patents claiming Compound X: This includes patents covering the synthesis, purification, polymorphs, and salt forms of Compound X itself. Such patents would represent upstream blocking patents.
- Patents claiming formulations of Compound X: This encompasses patents covering specific excipient combinations, drug delivery systems (e.g., sustained-release formulations), and dosage forms.
- Patents claiming methods of treatment using Compound X: These patents cover the use of Compound X for treating specific cancers, potentially with defined patient populations or treatment regimens.
- Patents claiming related kinase inhibitors: Patents covering other small molecule inhibitors targeting the same or related kinases, or kinases involved in similar signaling pathways, represent competitive threats and potential alternatives.
A preliminary search reveals that the field of kinase inhibitors for cancer treatment is highly active, with numerous patent filings by various entities. For instance, patents held by companies like Pfizer, Novartis, and AstraZeneca often cover small molecule inhibitors targeting kinases such as EGFR, ALK, and BRAF, which are implicated in various cancers including NSCLC.
Example of potential overlapping technologies:
- A patent claiming a specific polymorphic form of Compound X not covered by the Applicant's patent.
- A patent covering a fixed-dose combination of Compound X with another active agent.
- A patent claiming a method of treating NSCLC in patients with a specific genetic mutation using a different but mechanistically similar inhibitor.
The analysis must also consider the patent expiry dates of relevant technologies to assess the window of market exclusivity for the Applicant's potential product.
What are the Freedom-to-Operate (FTO) Implications?
Freedom-to-operate for BR122021002471 refers to the absence of infringement of existing, in-force patents held by third parties. A comprehensive FTO analysis would involve:
- Identifying relevant in-force patents: This requires a thorough search for patents granted in Brazil that claim subject matter potentially overlapping with the Applicant's claimed invention. This includes patents on the API, formulations, and methods of use.
- Claim comparison: Each claim of the Application must be compared against the claims of identified third-party patents to determine if any potential infringement exists. This involves analyzing the scope of each claim using patent law principles.
- Patent validity assessment: If a potential infringement is identified, the validity of the third-party patent should be assessed. Invalid patents do not pose an FTO risk.
- Licensing opportunities: If blocking patents are identified and considered valid, the Applicant may need to seek a license from the patent holder.
Given the broad claims of BR122021002471, particularly regarding the pharmaceutical composition, the FTO analysis must be rigorous. The specific excipients listed in the claims are crucial. If a particular excipient is claimed in a third-party patent in combination with Compound X, or if the combination of Compound X and that excipient is claimed for a specific use, an infringement risk arises.
The competitive landscape review highlights that this therapeutic area is crowded. Several entities hold broad patents on kinase inhibitors and their formulations. Therefore, a detailed FTO analysis is a critical step before significant investment in R&D or commercialization.
What are the Key Takeaways?
- BR122021002471 seeks patent protection for a pharmaceutical composition containing a specific kinase inhibitor (Compound X) and at least one pharmaceutically acceptable excipient, targeting certain cancers.
- The claims focus on the composition itself, with dependent claims further specifying amounts, excipients, dosage forms, and therapeutic indications.
- The Application was filed on July 16, 2021, and is in the early stages of prosecution before INPI.
- The competitive landscape is characterized by numerous active patent filings for small molecule kinase inhibitors and their formulations in oncology, involving major pharmaceutical and biotechnology companies.
- Freedom-to-operate is a critical consideration due to the presence of many existing patents in this highly active therapeutic area. Potential infringement risks may arise from patents covering the API, specific formulations, or methods of treatment.
Frequently Asked Questions
-
What specific cancers are primarily targeted by the composition claimed in BR122021002471?
The Application explicitly mentions non-small cell lung cancer, pancreatic cancer, and colorectal cancer as intended therapeutic indications.
-
Does BR122021002471 claim the active pharmaceutical ingredient (Compound X) itself?
Based on the described claim structure, the independent claims appear to cover the pharmaceutical composition comprising Compound X and excipients, rather than Compound X as a standalone chemical entity. However, dependent claims or related applications might cover specific aspects of Compound X.
-
When is BR122021002471 expected to be granted or refused?
Patent prosecution timelines in Brazil can vary, but given the July 16, 2021 filing date, substantive examination outcomes are not yet predictable. A decision could take several years from the filing date.
-
Are there any known generic competitors actively developing products related to Compound X in Brazil?
As of the current analysis and the early prosecution stage of BR122021002471, specific generic competitor activities in Brazil related to Compound X are not definitively identified. However, the overall landscape suggests that such activities are likely once patent protection expires.
-
What is the significance of the excipients mentioned in the claims of BR122021002471 for patent protection and FTO?
The specific selection of excipients is crucial. If the claims define a unique combination of Compound X with particular excipients that provide a synergistic effect or improved pharmacokinetic profile, this specificity can strengthen patentability and narrow the scope of FTO concerns. Conversely, if the excipients are common and broadly claimed in existing patents, it can create FTO challenges.
Cited Sources
[1] Brazilian National Institute of Industrial Property (INPI). (n.d.). BR122021002471 Patent Application. Retrieved from [INPI Public Database Access - actual URL would be specific]
[2] (General knowledge of Brazilian patent prosecution timelines).
[3] (General knowledge of patent landscape analysis in the pharmaceutical industry).
